Glenview, IL, United States of America

Laura Redden

USPTO Granted Patents = 1 


 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 99(Granted Patents)


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Laura Redden: Innovator in Pharmaceutical Formulations

Introduction

Laura Redden is a prominent inventor based in Glenview, IL (US). She has made significant contributions to the field of biotechnology, particularly in the development of pharmaceutical formulations that enhance patient comfort and treatment efficacy.

Latest Patents

Laura Redden holds a patent for "High concentration anti-TNFα antibody liquid formulations." This invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFα antibody, or an antigen-binding portion thereof. The formulation is designed to reduce pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. Additionally, the invention offers increased bioavailability upon subcutaneous administration into a subject, which is crucial for therapeutic proteins such as human anti-TNF-alpha antibodies.

Career Highlights

Laura is associated with AbbVie Biotechnology Ltd., where she continues to innovate in the field of biopharmaceuticals. Her work focuses on improving the delivery and effectiveness of therapeutic agents, which is vital for patient care.

Collaborations

Some of her notable coworkers include Michael Neu and Markus Tschoepe, who contribute to the collaborative environment that fosters innovation at AbbVie.

Conclusion

Laura Redden's work exemplifies the impact of innovative pharmaceutical formulations on patient treatment. Her contributions are paving the way for advancements in biotechnology and improving the quality of life for many patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…